everolimus
Not Tagged
['rcc,(-irccs),(-srcc),(-urcc)']
everolimus did not show a significant dfs or os advantage in adjuvant rcc. this study probably draws a line under the investigation of mtor (torc1/2) in rcc and draws a line under adjuvant targeted therapies in rcc. everolimus role is relatively limited. #asco22 
Interested in Urology Cancers, biomarkers and drug development.